CollPlant Biotechnologies - CLGN Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $12.50
  • Forecasted Upside: 219.69%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 1 Strong Buy Ratings
$3.91
▼ -0.01 (-0.26%)

This chart shows the closing price for CLGN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New CollPlant Biotechnologies Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CLGN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CLGN

Analyst Price Target is $12.50
▲ +219.69% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for CollPlant Biotechnologies in the last 3 months. The average price target is $12.50, with a high forecast of $14.00 and a low forecast of $11.00. The average price target represents a 219.69% upside from the last price of $3.91.

This chart shows the closing price for CLGN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 3 polled investment analysts is to buy stock in CollPlant Biotechnologies. This rating changed within the last month from a Strong Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/15/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/13/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/12/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/11/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/9/2024
  • 1 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/7/2024
  • 1 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/6/2024
  • 1 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/6/2024

Latest Recommendations

  • 1 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/29/2024HC WainwrightReiterated RatingBuy ➝ Buy$11.00 ➝ $11.00
11/27/2024D. Boral CapitalReiterated RatingBuy ➝ Buy$14.00 ➝ $14.00
8/21/2024HC WainwrightReiterated RatingBuy ➝ Buy$11.00 ➝ $11.00
8/5/2024EF Hutton Acquisition Co. IUpgradeStrong-Buy
5/30/2024HC WainwrightReiterated RatingBuy ➝ Buy$11.00 ➝ $11.00
4/5/2024HC WainwrightReiterated RatingBuy ➝ Buy$11.00
11/30/2023HC WainwrightReiterated RatingBuy ➝ Buy$11.00
8/25/2023HC WainwrightReiterated RatingBuy ➝ Buy$11.00
3/30/2023HC WainwrightLower TargetBuy$26.00 ➝ $11.00
2/17/2023Alliance Global PartnersInitiated CoverageBuy$22.75
2/9/2021HC WainwrightBoost TargetBuy$13.00 ➝ $26.00
12/2/2020HC WainwrightReiterated RatingBuy$13.00
5/28/2020HC WainwrightReiterated RatingBuy$11.00 ➝ $13.00
4/3/2020HC WainwrightBoost TargetBuy$7.00 ➝ $11.00
(Data available from 12/6/2019 forward)

News Sentiment Rating

0.35 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/10/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
6/9/2024
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/9/2024
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/8/2024
  • 1 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/7/2024
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/7/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/6/2024
  • 2 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/6/2024

Current Sentiment

  • 2 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
CollPlant Biotechnologies logo
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; as well as develops injectable breast implants and 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures. It has collaboration agreements with Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; International Society for Biofabrication; AbbVie; and STEMCELL Technologies. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. The company was founded in 2004 and is headquartered in Rehovot, Israel.
Read More

Today's Range

Now: $3.91
Low: $3.90
High: $3.99

50 Day Range

MA: $4.24
Low: $3.71
High: $4.93

52 Week Range

Now: $3.91
Low: $3.31
High: $6.99

Volume

6,162 shs

Average Volume

10,256 shs

Market Capitalization

$44.77 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.51

Frequently Asked Questions

What sell-side analysts currently cover shares of CollPlant Biotechnologies?

The following equities research analysts have issued research reports on CollPlant Biotechnologies in the last twelve months: D. Boral Capital, EF Hutton Acquisition Co. I, and HC Wainwright.
View the latest analyst ratings for CLGN.

What is the current price target for CollPlant Biotechnologies?

0 Wall Street analysts have set twelve-month price targets for CollPlant Biotechnologies in the last year. Their average twelve-month price target is $12.50, suggesting a possible upside of 218.9%. D. Boral Capital has the highest price target set, predicting CLGN will reach $14.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $11.00 for CollPlant Biotechnologies in the next year.
View the latest price targets for CLGN.

What is the current consensus analyst rating for CollPlant Biotechnologies?

CollPlant Biotechnologies currently has 2 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CLGN will outperform the market and that investors should add to their positions of CollPlant Biotechnologies.
View the latest ratings for CLGN.

What other companies compete with CollPlant Biotechnologies?

Other companies that are similar to CollPlant Biotechnologies include Nyxoah, Beauty Health, KORU Medical Systems, Lakeland Industries and Nevro. Learn More about companies similar to CollPlant Biotechnologies.

How do I contact CollPlant Biotechnologies' investor relations team?

CollPlant Biotechnologies' physical mailing address is 4 OPPENHEIMER ST. 11TH FLOOR, REHOVOT L3, 74140. The company's listed phone number is 972732325600 and its investor relations email address is [email protected]. The official website for CollPlant Biotechnologies is www.collplant.com. Learn More about contacing CollPlant Biotechnologies investor relations.